Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$646.87−6.22 (-0.95%)
Close on Nov 18, 2026Market cap $18.09BP/E 35.9Yield –
Medpace price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Medpace's price to sales ratio was 6.7× on Nov 11, 2026, against 7.1× a year earlier. Over the last 5 years it ranged from 3.6× to 7.4×, with a median of 5.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.7× | −0.0 |
| 2025 | Dec 31, 2025 | 6.7× | +1.7 |
| 2024 | Dec 31, 2024 | 5.0× | −0.3 |
| 2023 | Dec 29, 2023 | 5.3× | +0.5 |
| 2022 | Dec 30, 2022 | 4.8× | −2.3 |
| 2021 | Dec 31, 2021 | 7.2× | +1.6 |
| 2020 | Dec 31, 2020 | 5.6× | +1.9 |
| 2019 | Dec 31, 2019 | 3.7× | +0.7 |
| 2018 | Dec 31, 2018 | 3.0× | −0.2 |
| 2017 | Dec 29, 2017 | 3.2× | −0.8 |
| 2016 | Dec 30, 2016 | 4.1× | – |
See a number that looks wrong?